125 results about "Amoxicillin" patented technology

A method for separating amoxicillin and phenylacetic acid from reaction solution in one-step enzymatic synthesis of amoxicillin is provided. The method employs immobilized penicillin acylase mutant to catalyze the one-step synthesis of amoxicillin from penicillin potassium, and develops a separation process for the resulting reaction mixture. The technical scheme mainly comprises: Firstly separating the immobilized penicillin acylase mutant from the reaction solution through filtration; subsequently isolating amoxicillin via crystallization; followed by separating and recovering phenylacetic acid through toluene extraction and back extraction. This separation method enables rapid and efficient isolation of amoxicillin with high production yield, achieving an average crystallization rate of 93.22%. Concurrently, it demonstrates effective separation and recovery of phenylacetic acid while allowing recyclable use of the toluene extractant.

The invention belongs to the technical field of separation of products for synthesizing antibiotics by an enzymic method, and particularly relates to a method for separating and recycling an amoxicillin product synthesized by a one-step method based on catalysis of kluyveromyces citricacidophilus beta subunit G385 mutant penicillin acylase. An immobilized penicillin acylase mutant is used for catalyzing penicillin potassium to synthesize amoxicillin in one step, a set of method for separating amoxicillin and phenylacetic acid is developed for an obtained reaction mixture, and the technical scheme mainly comprises the following steps: firstly, separating the immobilized penicillin acylase mutant from a reaction solution through filtration; then, amoxicillin is separated out through crystallization; and then crystallizing, separating and recovering phenylacetic acid through toluene extraction, back extraction and the like. According to the separation method, the amoxicillin can be rapidly and efficiently separated, the yield of the amoxicillin is relatively high, and the average crystallization rate reaches 93.22%; meanwhile, the separation and recovery effects of phenylacetic acid are good; and the extraction agent toluene can be recycled.

The invention relates to the technical field of nano-enzyme preparation and electrochemical and colorimetric dual-mode sensing, and particularly discloses a Mn3Fe2.7-atC nano-enzyme, a preparation method thereof and application of the Mn3Fe2.7-atC nano-enzyme in determination of amoxicillin content. The preparation method of the Mn3Fe2.7 at C nano-enzyme is characterized by comprising the following steps: dissolving manganese chloride and trisodium citrate in water to prepare a solution A; dissolving potassium ferricyanide in water to prepare a solution B; adding the solution B into the solution A under a stirring condition, continuously stirring for 16-32 hours after the solution B is added, carrying out suction filtration, and drying the obtained precipitate to obtain a ferromanganese prussian blue analogue precursor; and placing the ferromanganese prussian blue analogue precursor in a tubular furnace, carrying out pyrolysis, and after the pyrolysis is finished, carrying out acid soaking, washing and drying to obtain the Mn3Fe2.7 at C nano-enzyme. When the Mn3Fe2.7 (at) C nano-enzyme is used for measuring the content of amoxicillin, the accuracy is good, and meanwhile, the Mn3Fe2.7 (at) C nano-enzyme has the advantages of interference resistance, stability, good recovery rate and the like.

The invention provides a penicillin G acylase AxPGA mutant, an expression plasmid, a genetically engineered bacterium and application, and belongs to the technical field of biocatalysts. The mutant is obtained by mutation of any one or more of the following sites of an amino acid sequence as shown in SEQ ID NO: 1: (1) methionine at the 103rd site is substituted by cysteine, (2) tyrosine at the 424th site is substituted by phenylalanine, (3) tyrosine at the 442nd site is substituted by phenylalanine, and (4) tyrosine at the 451st site is substituted by alanine. The obtained penicillin G acylase AxPGA mutant is relatively high in enzyme activity and can be applied to high-conversion-rate and high-yield synthesis of beta-lactam antibiotics such as benicillin and amoxicillin.

The invention discloses a bacteriostatic composition which comprises a synergist and a bacteriostatic agent, the synergist is ethyl phenylacetate or a derivative thereof, and the bacteriostatic agent is selected from hydrogen peroxide, beta-lactam antibiotics, macrolide antibiotics and aminoglycoside antibiotics. The synergist disclosed by the invention is wide in synergistic effect spectrum range, and has a remarkable synergistic bacteriostatic effect when being combined with hydrogen peroxide, amoxicillin, ampicillin, benzylpenicillin potassium, erythromycin, azithromycin and amikacin; the antibacterial effect is weak when the compound is independently used, but the virulence of staphylococcus aureus can be remarkably reduced, the formation of hemolysin, staphylococcus flavin, enterotoxin and a biofilm can be inhibited, and meanwhile, the selective pressure on bacteria is favorably reduced due to the relatively low antibacterial activity, so that the occurrence of drug resistance is delayed; the method is suitable for various application scenes such as food processing industry.

The present invention belongs to the field of biotechnology, and specifically relates to the use of the CD630_27900 gene in reducing the tolerance of Clostridium difficile. Knocking out the CD630_27900 gene can reduce the tolerance of Clostridium difficile to acidic environments and antibiotics and reduce its cytotoxicity; the sequence of the CD630_27900 gene is shown in SEQ ID NO.1; the antibiotics include ampicillin, metronidazole, amoxicillin, vancomycin, norfloxacin, cefoxitin, clindamycin and kanamycin. The research results of the present invention suggest that the CD630_27900 gene can be used as a target for inhibiting the drug resistance and reducing the toxicity of Clostridium difficile, providing a new idea for the treatment of Clostridium difficile infection (CDI).

The invention belongs to the field of veterinary drugs, and particularly relates to water-soluble amoxicillin powder which comprises the following components: 50-60 parts of amoxicillin, 5-10 parts of polyvinyl alcohol modified beta-cyclodextrin, 1-3 parts of tryptophan, 20-30 parts of a filler and 0.5-1 part of a flavoring agent. The water-soluble amoxicillin powder disclosed by the invention has an excellent slow-release effect and storage stability.

The invention discloses a compound preparation capsule and a preparation method thereof, wherein the compound preparation capsule is composed of Vonoprasone or a pharmaceutical salt microtablet thereof, an amoxicillin microtablet and a rifampicin or rifampetine microtablet. The Vonoprazan is a novel potassium ion competitive acid blocker, and the compound preparation capsule is used for treating gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and helicobacter pylori infection and helicobacter pylori infection gastritis in the stomach after early gastric cancer endoscopic therapy. According to the compound preparation capsule, the cure rate of helicobacter pylori can be increased, the drug resistance can be reduced, and a better treatment choice is provided for clinical patients.

The present patent invents a method for detecting amoxicillin in breast milk based on the colorimetric method of aptamer combined with gold nanoparticles (AuNPs) and a smartphone. It is characterized in that the aptamer conjugated with gold nanoparticles specifically binds to amoxicillin in breast milk. In the presence of a salt solution, different concentrations of amoxicillin can cause different degrees of aggregation of gold nanoparticles, resulting in different colors of the solution. The color of the solution is collected by an image acquisition device and transmitted to a smartphone, and the smartphone analyzes the change in the RGB value of the image to obtain a quantitative result, thereby realizing the detection of residual amoxicillin in real breast milk samples. This method can obtain quantitative detection results in a short time, and has the advantages of high sensitivity, good specificity, low cost, simple operation, etc., and is easy to promote and apply.

The invention belongs to the technical field of product separation in enzymatic synthesis of antibiotics, and particularly relates to a method for separating and purifying amoxicillin and phenylacetic acid in the production process of amoxicillin. An immobilized penicillin acylase mutant is used for catalyzing penicillin potassium to synthesize amoxicillin in one step, a set of method for separating amoxicillin and phenylacetic acid is developed for an obtained reaction mixture, and the technical scheme mainly comprises the following steps: firstly, separating the immobilized penicillin acylase mutant from a reaction solution through filtration; then, amoxicillin is separated out through crystallization; and then crystallizing, separating and recovering phenylacetic acid through toluene extraction, back extraction and the like. According to the separation method, the amoxicillin can be rapidly and efficiently separated, the yield of the amoxicillin is relatively high, and the average crystallization rate reaches 93.22%; meanwhile, the separation and recovery effects of phenylacetic acid are good; and the extraction agent toluene can be recycled.

The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder, and belongs to the technical field of compound amoxicillin, and the method comprises the following steps: (1) simulating a gastric acid environment, and respectively adding different compound amoxicillin powder samples to obtain different sample solutions; (2) simulating a small intestine environment for different sample solutions obtained in the step (1); and (3) sampling different sample solutions after the step (2), measuring the minimum inhibitory concentration, and comparing the effect of the compound amoxicillin powder sample to evaluate. The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder. The method is simple to operate and can quickly and accurately evaluate the effect of the compound amoxicillin powder.

The invention discloses a method for detecting related substances in an amoxicillin raw material and a preparation thereof, and relates to the technical field of pharmaceutical analysis, HPLC conditions are as follows: the elution gradient is 0-5 min: 100% mobile phase A; in 5-25 min, 100%-94% of the mobile phase A and 0-6% of the mobile phase B are adopted; 25-40 min, 94%-84% of the mobile phase A and 6%-16% of the mobile phase B are adopted; 40-50 minutes: 84% of the mobile phase A and 16% of the mobile phase B; 50-51min: 84% of the mobile phase A, 100% of the mobile phase A and 16-0% of the mobile phase B; and in 51-60 min, 100% of the mobile phase A is adopted. The method for detecting the related substances of the amoxicillin related varieties, which is recorded and published by various Chinese pharmacopoeias and literatures, is confirmed, and a set of more effective high performance liquid chromatography is established and verified by screening and optimizing liquid phase conditions such as chromatographic columns and mobile phases, particularly chromatographic column brands, fillers, models and the like; the quality control can be simultaneously carried out on process impurities, degradation impurities, polymers and other organic impurities of amoxicillin raw materials and preparations thereof, so that the occurrence of adverse reactions such as anaphylaxis and the like is reduced, and the safety and effectiveness of medication are ensured.

The invention relates to the technical field of pharmaceutical equipment, and discloses a reaction tank based on intelligent production of amoxicillin sodium, the reaction tank comprises a shell, a stirring mechanism arranged at the top of the shell, and a switching mechanism arranged at the top of the stirring mechanism; the stirring mechanism is used for mixing raw materials, and the switching mechanism is used for cleaning crystals attached to the stirring mechanism; the stirring mechanism comprises a driving unit arranged at the top of the shell and used for providing power, a rotating shaft arranged at the bottom of the driving unit, a rotating arm arranged in the middle of the rotating shaft, a plurality of vertical rods arranged at the bottom of the rotating arm in a linear array mode, and a lifting block arranged on the outer side of the rotating shaft; the protruding block is arranged on the side, close to the rotary arm, of the lifting block and can ascend and descend along with the lifting block. And by arranging the stirring mechanism, heat can be uniformly distributed when the raw materials are stirred, so that the uniformity and the stability of temperature control are improved.

This invention discloses a penicillin G acylase mutant SEQ ID NO:3, which can efficiently catalyze the reaction of substrate 6-APA with DHPGM to produce amoxicillin. The synthesis / hydrolysis ratio S / H reaches a maximum of 18.1. When the side chain to parent nucleus ratio is 1.05:1, the conversion rate of parent nucleus 6-APA reaches more than 99.0%. This mutant has high thermal stability, which helps to improve the efficiency of industrial production of amoxicillin.

The invention belongs to the technical field of enzyme catalysis, and particularly relates to recombinant penicillin G acylase, encoding nucleotide and application of the recombinant penicillin G acylase. Compared with an amino acid sequence shown in SEQ ID NO. 1, the mutant has the advantages that the mutation mode is F24 beta R; or F146 [alpha] K amp; f24 [beta] R; or F146 [alpha] K amp; f24 [beta] R amp; f71 [beta] Y; or F146 [alpha] K amp; f24 [beta] R amp; f71 [beta] Y amp; n241 [beta] K amp; and G385 [beta] Y. According to the invention, wild type penicillin acylase is mutated to obtain penicillin acylase with coordinated enzymatic activity of hydrolysis and synthesis. The method can be used for synthesis production of beta-lactam antibiotics, especially for one-step preparation of amoxicillin by catalyzing penicillin potassium salt and the like, and separation of an intermediate 6-APA is avoided. The invention provides a key enzyme for efficient preparation of beta-lactam antibiotics, and greatly promotes the innovation of a beta-lactam antibiotic preparation technology.

This invention provides a MnO2@CDs composite material for the visual detection of amoxicillin and its preparation method, relating to the field of analytical detection technology. The MnO2@CDs constructed in this invention can be used for both fluorescence and colorimetric detection of amoxicillin. Due to the resonant energy transfer between CDs and MnO2, the fluorescence of CDs is quenched. In the presence of AMO, MnO2 is degraded by AMO, releasing CDs, and its blue fluorescence is restored. In colorimetric detection, MnO2@CDs exhibit excellent oxidase-like properties, capable of oxidizing colorless TMB to yellow TMB. 2+ AMO has strong reducing properties and inhibits oxidation reactions. In the presence of AMO, it can promote the oxidation of TMB. 2+ When AMO is reduced to TMB, the solution color gradually changes from yellow to colorless as the AMO concentration increases, resulting in a vibrant color change and enabling the visual detection of AMO.

This invention belongs to the field of product separation technology in enzymatic antibiotic synthesis, and particularly relates to a method for separating and recovering amoxicillin products from a one-step synthesis catalyzed by a Kluyveromycin β-subunit G385 mutant penicillin acylase. This application uses an immobilized penicillin acylase mutant to catalyze the one-step synthesis of amoxicillin from potassium penicillin. A method for separating amoxicillin and phenylacetic acid is developed for the obtained reaction mixture. The technical solution mainly includes: firstly, separating the immobilized penicillin acylase mutant from the reaction solution by filtration; then separating amoxicillin by crystallization; and finally, separating and recovering phenylacetic acid by toluene extraction, back-extraction, etc. This separation method can rapidly and efficiently separate amoxicillin with a high yield, with an average crystallization rate of 93.22%; simultaneously, the separation and recovery of phenylacetic acid is good; and the extractant toluene can be recycled.

The invention belongs to the technical field of product separation of antibiotics synthesized by an enzyme method, and particularly relates to a product separation and recovery process of amoxicillin synthesized by a one-step method. An immobilized penicillin acylase mutant is used for catalyzing penicillin potassium to synthesize amoxicillin in one step, a set of method for separating amoxicillin and phenylacetic acid is developed for an obtained reaction mixture, and the technical scheme mainly comprises the following steps: firstly, separating the immobilized penicillin acylase mutant from a reaction solution through filtration; then, amoxicillin is separated out through crystallization; and then crystallizing, separating and recovering phenylacetic acid through toluene extraction, back extraction and the like. According to the separation method, the amoxicillin can be rapidly and efficiently separated, the yield of the amoxicillin is relatively high, and the average crystallization rate reaches 93.22%; meanwhile, the separation and recovery effects of phenylacetic acid are good; and the extraction agent toluene can be recycled.

The application provides a preparation method of a magnetic multi-level hole iron-nitrogen-carbon catalyst and belongs to the field of new advanced oxidation catalyst materials. The preparation method is as follows: (1) dissolving iron nitrate nonahydrate in N,N-dimethylformamide, dissolving 2-amino terephthalic acid in N,N-dimethylformamide, and then mixing the two liquids; (2) transferring the mixed liquid into a closed reaction container and heating into a gel in a blast drying oven; (3) washing with N,N-dimethylformamide and ethanol, drying in a fume hood at room temperature to obtain a multi-level hole metal organic framework gel FeBDC-NH2; (4) transferring into a porcelain boat and placing into a tube furnace to react at high temperature under an anaerobic atmosphere, so that the magnetic multi-level hole iron-nitrogen-carbon catalyst is obtained. The catalyst prepared by the method has rich defects and excellent electron transfer capacity, the multi-level hole structure of the material accelerates the mass transfer efficiency of the catalytic reaction, the material magnetism facilitates recycling, and the material can directionally catalyze the degradation of amoxicillin by a non-free radical path through persulfate.

The invention provides Kineococcus G2 and application of the Kineococcus G2 in preparation of a pigment with antioxidant activity, the Kineococcus new strain G2 is CCTCC No. M20242602, the strain is spherical, the size is 1.0 * 1.5 mu m, the optimal growth temperature is 30-37 DEG C, the pH value is 7.0-9.0, and the salt concentration is 1.0%-2.0%. The strain G2 is not sensitive to bacitracin, ciprofloxacin and norfloxacin, and is sensitive to novobiocin, polymyxin, gentamicin, piperacillin, ofloxacin, erythromycin, streptomycin, kanamycin, rifampicin, ampicillin, vancomycin, carbenicillin, chloramphenicol, tetracycline, penicillin, cefoperazone, oxacillin, amoxicillin and neomycin. Pigment generated by fermentation of the G2 strain has good antioxidant activity, and when the concentration is 10 micrograms / mL, the scavenging activity on DPPH is 25.00%, the scavenging activity on hydroxyl radicals is 80.58%, and the iron ion reducing capacity is 1.57, which are all higher than those of contrast beta-carotenoid. The application of the new Kineococcus strain G2 can lay a foundation for the research of antioxidant drugs such as medical treatment and health care product development.

The invention discloses stenotrophomonas maltophilia and application of the stenotrophomonas maltophilia in polluted environment treatment. According to the invention, the stenotrophomonas maltophilia capable of degrading antibiotics is separated and identified in a seawater sample for the first time, and research shows that the DA02 strain can degrade antibiotics such as penicillin potassium, amoxicillin and ceftriaxone sodium, and has an efficient degradation effect on the antibiotics of the ceftriaxone sodium; and in addition, a good degradation effect is also achieved in high-concentration antibiotic drugs, the degradation rate is increased along with the increase of the antibiotic concentration, and the degradation effect is always kept stable along with the prolonging of time. It is shown that the DA02 strain serves as a ceftriaxone sodium efficient degrading bacterium, is not affected by the drug concentration of the ceftriaxone sodium efficient degrading bacterium, can be better applied to degradation of high-concentration antibiotics in the antibiotic-polluted environment, and provides more efficient treatment methods and ways for the antibiotic-polluted environment.

The invention relates to a compound medicine composition and application thereof in resisting helicobacter pylori infection, in particular to the compound medicine composition, a medicine preparation, a preparation method and application, and the composition comprises at least two selected from the following components: (I) Vonoprazan or pharmaceutically acceptable salt thereof, (II) Vonoprazan or pharmaceutically acceptable salt thereof, (III) Vonoprazan or pharmaceutically acceptable salt thereof, (III) Vonoprazan or pharmaceutically acceptable salt thereof, (III) Vonoprazan or pharmaceutically acceptable salt thereof and (III) Vonoprazan or pharmaceutically acceptable salt thereof; (II) amoxicillin or a pharmaceutically acceptable salt thereof; (III) clarithromycin; according to the composition prepared by compounding different anti-infection active ingredients, the problems of patient compliance and medication convenience can be effectively solved, for example, the tablet dosage is reduced, wrong taking, missing taking, excessive taking and the like of a patient are avoided, the stability and safety of the preparation can be accidentally improved, and the content of harmful impurities is particularly reduced.

The application provides a penicillin G acylase Ax The PGA mutant and the expression plasmid, the genetically engineered bacteria and the application belong to the technical field of biological catalysts. The PGA mutant is obtained by mutation of any one or more of the following positions of the amino acid sequence shown in SEQ ID NO: 1: (1) methionine at the 103th position is replaced by cysteine, (2) tyrosine at the 424th position is replaced by phenylalanine, (3) tyrosine at the 442th position is replaced by phenylalanine, and (4) tyrosine at the 451th position is replaced by alanine. The obtained penicillin G acylase Ax The PGA mutant has high enzyme activity and can be applied to high-conversion-rate and high-yield synthesis of beta-lactam antibiotics such as benzylpenicillin and amoxicillin.

The invention belongs to the technical field of enzyme catalysis, and particularly relates to penicillin acylase for synthesizing beta-lactam antibiotics. Compared with an amino acid sequence shown in SEQ ID NO. 1, the mutant has the advantages that the mutation mode is F146 alphaK; or F146 [alpha] K amp; g385 [beta] Y; or F146 [alpha] K amp; g385 [beta] R is shown in the description. According to the penicillin acylase mutant disclosed by the invention, penicillin acylase from kluyvera citrophila (Kluyvera citrophila) is mutated, so that the penicillin acylase mutant which is strong in hydrolytic activity and synthetic activity and is coordinated in two enzyme activities is obtained. The method can be used for synthesis production of beta-lactam antibiotics, especially for one-step preparation of amoxicillin by catalyzing penicillin potassium salt and the like, and separation of an intermediate 6-APA is avoided. The invention provides a key enzyme for efficient preparation of beta-lactam antibiotics, and greatly promotes the innovation of a beta-lactam antibiotic preparation technology.

The invention belongs to the technical field of microorganisms, and particularly relates to multi-drug-resistant klebsiella pneumoniae and application thereof in construction of a pneumonia animal model. Specifically, the multi-drug-resistant klebsiella pneumoniae BKP919 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.36301, and the multi-drug-resistant klebsiella pneumoniae BKP919 has wide drug resistance to various antibiotics such as amoxicillin, piperacillin and the like. The bacterial liquid of the strain is used for carrying out one-time intratracheal instillation on a mouse in a nasal instillation manner, and a stable severe pneumonia model can be established within 48-72 hours. The model preparation method is simple to operate and high in efficiency, and the model mouse has remarkable pneumonia symptoms, obvious pathological change and good related index stability, and can be used for pathogenesis research and targeted drug development of multi-drug-resistant klebsiella pneumonia infected pneumonia, so that the model has good practical application value.

This invention discloses an amoxicillin capsule and its preparation method, relating to the field of pharmaceutical technology. The preparation method includes the following steps: S1: Wet ball milling of amoxicillin trihydrate and hydroxypropyl methylcellulose E5, followed by spray drying to obtain surface-modified amoxicillin trihydrate micropowder; S2: Mixing the surface-modified amoxicillin trihydrate with a filler; S3: Fluidized bed granulation, including spray granulation using aqueous ethanol as a wetting agent followed by drying; S4: Granulation and mixing, including granulating the dried particles and then adding a disintegrant, a flow aid, and a lubricant; S5: Capsule filling, including capsule filling with controlled ambient humidity. This invention achieves the goals of maintaining the crystal stability of amoxicillin trihydrate, inhibiting hydrothermal degradation, and ensuring dissolution behavior consistent with the original drug by combining wet ball milling of hydroxypropyl methylcellulose E5 with spray drying for surface modification, fluidized bed granulation with aqueous ethanol, and controlling the humidity of the filling environment.

The invention belongs to the technical field of enzyme catalysis, and particularly relates to a high-activity penicillin G acylase mutant, encoding nucleotide and application of the high-activity penicillin G acylase mutant. Compared with an amino acid sequence shown in SEQ ID NO. 1, the mutant has the advantages that the mutation mode is F71betaY; or F146 [alpha] K amp; f71 [beta] Y; or F146 [alpha] K amp; f71 [beta] Y amp; n241 [beta] K; or F146 [alpha] K amp; f71 [beta] Y amp; n241 [beta] K amp; and G385 [beta] Y. Through site-directed mutagenesis, the penicillin acylase mutant with strong hydrolytic activity and synthetic activity and coordinated two enzyme activities is obtained. The method can be used for synthesis production of beta-lactam antibiotics, especially for one-step preparation of amoxicillin by catalyzing penicillin potassium salt and the like, and separation of an intermediate 6-APA is avoided. The invention provides a key enzyme for efficient preparation of beta-lactam antibiotics, and greatly promotes the innovation of a beta-lactam antibiotic preparation technology.

1. Name of the Design Product: Packaging Box (Amoxicillin Granules). 2. Use of the Design Product: For packaging medicines. 3. Design Key Points of the Design Product: Lies in the combination of shape, pattern and color. 4. Picture or Photo Most Indicating the Design Key Points: Front View. 5. The claimed design includes color.

The application belongs to the technical field of medicine, and particularly relates to a compound montmorillonite particle for treating Helicobacter pylori infection and a preparation method thereof. The compound montmorillonite particle for treating Helicobacter pylori infection comprises A component and B component, wherein the A component is prepared from the following raw materials according to weight fractions: montmorillonite 50-65 parts; filler a 5-15 parts; binder a 0.1-1.5 parts; disintegrant 2-7 parts; the B component is prepared from the following raw materials according to weight fractions: amoxicillin 5-10 parts; rifabutin 0.2-0.5 parts; filler b 4-15 parts; binder b 1-6 parts; disintegrant 2-7 parts. The compound montmorillonite particle for treating Helicobacter pylori infection provided by the application has no drug resistance problem, and improves the compliance of patients with dysphagia and children to drug administration; and the application further provides a preparation method thereof, which is simple to operate and stable in process.

The invention provides an amoxicillin preparation and a preparation method thereof, and the preparation method comprises the following steps: preparing a temperature-sensitive polymer solution, uniformly mixing amoxicillin powder with chitosan and pretreated lactose, adding the mixture into the temperature-sensitive polymer solution, and carrying out spray drying to form amoxicillin-polymer composite particles, and carrying out multi-layer temperature sensitive coating treatment and curing. According to the invention, by using the temperature-sensitive polymer PNIPAM, the drug can be quickly released at an inflammation part under a high-temperature condition, the drug effect is improved, and the side effect is reduced. Due to the addition of the chitosan and the pretreated lactose, the solubility and bioavailability of the amoxicillin are improved, and the uniform distribution and sustained release of the medicine are ensured. The use of the plasticizer glycerol enhances the flexibility and stability of the polymer, and through curing treatment, the stability of the coating layer and the controllability of drug release are improved. The amoxicillin preparation disclosed by the invention has remarkable advantages in the aspects of improving the curative effect, reducing the side effect and improving the compliance of a patient.